The Trump administration proposed a new rule Thursday aimed at lowering prescription drug costs for Medicare patients by limiting how much certain hospitals can charge for discounted medications. The proposal targets hospitals that participate in the federal 340B drug pricing program, which allows qualifying facilities that serve low-income communities to purchase outpatient prescription drugs at significantly reduced prices.

Under the current system, many hospitals buy these medications at a discount but receive much higher Medicare reimbursements when administering them, allowing them to keep the difference. The administration says the new rule would tie reimbursements more closely to hospitals’ acquisition costs, reducing out-of-pocket expenses for Medicare beneficiaries.

The White House estimates the proposal would save Medicare patients $1.1 billion next year, with the average affected beneficiary saving about $800 annually in copayments. Officials also project roughly $20 billion in savings over the next decade. Hospital groups quickly criticized the proposal, arguing the reduced reimbursements would strain finances and make it harder for hospitals serving vulnerable communities to maintain essential healthcare services.

The proposal challenges a payment system that Americans have long criticized, saying it has allowed some hospitals to earn large profits on medications purchased through a program originally intended to help low-income patients. By tying Medicare reimbursements more closely to what hospitals actually pay for those drugs, the Trump administration is attempting to redirect more of the savings to patients rather than healthcare providers…

2026 has been the year of the energy shock. But while the world fixated on oil, another strategic resource staged one of the sharpest rallies in commodities: lithium.

Battery grade lithium carbonate has roughly doubled over the past year, to around $20,000 a ton, near three year highs, as supply tightened and demand from EVs, grid storage, and AI data centers surged. Morgan Stanley now forecasts a global lithium deficit in 2026.

EnergyX is positioned right in the middle of it. Its Project Lonestar™ demonstration plant in Texas is now producing battery grade lithium, one of the largest direct lithium extraction facilities in the United States. At full commercial scale, the company projects up to 50,000 tons a year and roughly $1 billion in annual revenue at current market prices.*

Backed by GM, POSCO, Eni, and the DOE. 50,000+ investors. $180M+ raised. Shares are $13 before the July 16 deadline.

[Claim your stake in the lithium boom →]

Many hospitals would lose a substantial source of revenue if the rule were to take effect. Health systems often use money generated through the 340B program to help cover the cost of treating uninsured and low-income patients. Hospital groups believe that lower Medicare reimbursements could leave them with fewer resources for community clinics, specialty care, and other services.

Billions of dollars in federal drug discounts are at the center of the issue. While the Trump administration wants more of the savings to reduce Medicare patients' out-of-pocket costs, hospitals contend that these funds help pay for community clinics, specialty care, and treatment for uninsured patients.

If the rule is finalized, many Medicare patients who receive expensive outpatient drugs would see lower copayments without changing their coverage or prescription plan. The administration estimates the average affected beneficiary would save about $800 a year, providing meaningful relief for many seniors who rely on costly treatments for conditions such as cancer, autoimmune diseases, and other chronic illnesses that often require hospital-administered medications.

If passed, the proposal would also likely have a strong influence on where patients choose to receive care. Hospitals that lose reimbursement revenue would be forced to reevaluate which services they offer and how they deliver certain treatments, particularly in communities where operating margins are already thin.

The decision is also likely to alter the incentives built into Medicare, as hospitals would have fewer opportunities to generate revenue from discounted drugs, creating greater pressure to control costs through efficiency rather than reimbursement formulas. Such a change could have a staggering influence on how Medicare payment policies are designed moving forward.

*Disclaimer: Energy Exploration Technologies, Inc. (“we”, “us”, “our”, and “EnergyX” is conducting an offering of securities pursuant to Regulation A of the Securities Act of 1933, as amended. An offering statement covering this offering has been qualified by the U.S. Securities and Exchange Commission (the “SEC”). Neither this communication nor any of its content constitutes an offer to sell, solicitation of an offer to buy or a recommendation for any of our securities by our company or any third party. Offers and sales of the securities are being made solely by means of the qualified offering circular. Investing in our securities involves significant risks. Before investing, you should consult with your financial advisor, accountant, and/or attorney legal, and carefully review the qualified offering circular (including the “Risk Factors” section) and any offering circular supplements.

The most recent qualified offering circular is available at https://www.sec.gov/Archives/edgar/data/1830166/000149315226017123/form253g2.htm. The most recent qualified offering circular and any supplements can also be found on the SEC’s EDGAR filing database, available at www.sec.gov/edgar/search/. Prospective investors should note that neither the SEC nor any federal or state securities commission or regulatory authority has approved or recommended our securities or determined that our offering circular is truthful or complete. Any representation to the contrary is unlawful. We are not a broker-dealer or investment adviser registered under the Securities Exchange Act of 1934 or the Investment Advisers Act of 1940. No communication made by us or any of our affiliates, through this communication or any other medium, should be construed as a recommendation to purchase, sell, or hold any securities, or as investment, tax, financial, accounting, legal, regulatory, or compliance advice. Neither this communication nor any of its content constitutes an offer to sell, solicitation of an offer to buy or a recommendation for any of our securities by our company or any third party. The content presented here is provided for general information purposes only and is not intended to solicit the purchase of securities or to be used as investment, legal or tax advice. Statement Regarding Forward-Looking Statements The information presented herein may include forward-looking statements, estimates, or projections regarding our anticipated future performance. If present, these statements are subject to risks, uncertainties, and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms, and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections, if any, are based upon various assumptions made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of any such forward-looking statements, estimates or projections. Our actual performance may be materially different from any such statements, estimates or projections. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectations.